Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Incyte Corp (NQ: INCY )

80.96 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 65,303
Open 80.96
Bid (Size) 80.50 (1)
Ask (Size) 84.50 (1)
Prev. Close 80.96
Today's Range 80.96 - 80.96
52wk Range 65.07 - 86.29
Shares Outstanding 222,430,635
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Analyst Ratings for Incyte
 
Via Benzinga
Incyte, Haemonetics Post Earnings Beats; One Surges Within Buy Zone
Haemonetics stock rose within a buy zone on Tuesday, but Incyte stock toppled. 
Via Investor's Business Daily

Performance

YTD
+1.77%
+1.77%
1 Month
+2.73%
+2.73%
3 Month
+5.57%
+5.57%
6 Month
+9.81%
+9.81%
1 Year
+10.37%
+10.37%

More News

Read More
Incyte Q4 Earnings Beat Street View, But Guidance Is Conservative Says Analyst
Via Benzinga
Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs
From Incyte
Via Business Wire
Earnings Outlook For Incyte
Via Benzinga
2 Steady Stocks to Buy in a Recession
Via The Motley Fool
Golden Cross Appears Before Incyte Investors
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023
Via Benzinga
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Incyte Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
Via Investor's Business Daily
7 Biotech Stocks That Will Make You Rich in 10 Years
Via InvestorPlace
BriaCell Therapeutics' Mission: Destroy Breast & Prostate Cancers
Via Talk Markets
Incyte to Report Fourth Quarter and Year-End 2022 Financial Results
From Incyte
Via Business Wire
Why These 7 Healthcare Stocks Could Soar in 2023
Via InvestorPlace
Week In Review: Ten Biggest 2022 China Biopharma Deals Worth $21.5 Billion
Via Talk Markets
2 Cathie Wood Stocks to Buy and Hold Through 2023 and Beyond
Via The Motley Fool
The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond
Via InvestorPlace
Cramer Says He's 'Always Liked' This Drug Company
Via Benzinga
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
BriaCell's Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients
Via Benzinga
Incyte’s Novel Mutant CALR Antibody Unveiled at ASH 2022 Plenary Scientific Session
From Incyte
Via Business Wire
Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis (MF) Presented at ASH 2022
From Incyte
Via Business Wire
Incyte and CMS Announce Collaboration and License Agreement for Ruxolitinib Cream in Greater China and Southeast Asia
From Incyte
Via Business Wire
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
Incyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid Tumors
From Incyte and Mirati
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.